Fate tempted by $3 billion offer from J&J

3 April 2020
jnjn_flickr_big

Shares in Fate Therapeutics (Nasdaq: FATE) are up more than a tenth after the cellular immunotherapy specialist unveiled a global collaboration and option agreement with Johnson & Johnson (NYSE: JNJ).

J&J’s pharma arm, Janssen, will contribute proprietary antigen binding domains as part of an R&D project aimed at developing novel CAR-NK and CAR-T Cell product candidates.

Fate Therapeutics will use its iPSC product platform to research and preclinically develop the candidates, and will receive $50 million in cash and $50 million for an equity stake at $30 per share.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology